Pasha Davoudian
he/him/his
DownloadHi-Res Photo
About
Copy Link
Biography
Pasha received his B.A. in neuroscience with highest distinction from the University of Virginia where he studied thalamocortical circuits involved in absence epilepsy. Following his undergraduate training, he was a research associate at the Allen Institute for Brain Science where he described the patterns of connectivity and characterized synaptic physiological properties of mouse and human neocortical networks. At Yale, he conducted his thesis work examining cellular, synaptic, and circuit effects of psychedelics.
Last Updated on December 17, 2024.
Education & Training
- Research Associate
- Allen Institute for Brain Science (2018)
- BA
- University of Virginia, Neuroscience (2016)
Research
Copy Link
Overview
Medical Research Interests
Antidepressive Agents; Biophysics; Dendrites; Ion Channels; Ketamine; Neurobiology; Neurology; Neuronal Plasticity; Neurophysiology; Psilocybin; Psychiatry; Synapses; Synaptic Transmission
ORCID
0000-0002-5096-7610- View Lab Website
Kwan Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Pasha Davoudian's published research.
Publications Timeline
A big-picture view of Pasha Davoudian's research output by year.
Research Interests
Research topics Pasha Davoudian is interested in exploring.
Alex Kwan, PhD
Clara Liao, BA
Neil K. Savalia
Alfred Kaye, MD, PhD
Alicia Che, PhD
Greg Rhee, PhD, FACE
19Publications
1,813Citations
Psilocybin
Synapses
Ketamine
Neuronal Plasticity
Synaptic Transmission
Dendrites
Publications
2025
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Jiang Q, Shao L, Yao S, Savalia N, Gilbert A, Davoudian P, Nothnagel J, Tian G, Hung T, Lai H, Beier K, Zeng H, Kwan A. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell 2025, 189: 659-675.e22. PMID: 41352354, PMCID: PMC12695013, DOI: 10.1016/j.cell.2025.11.009.Peer-Reviewed Original ResearchCitationsAltmetricPublisher Correction: Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
Shao L, Liao C, Davoudian P, Savalia N, Jiang Q, Wojtasiewicz C, Tan D, Nothnagel J, Liu R, Woodburn S, Bilash O, Kim H, Che A, Kwan A. Publisher Correction: Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors. Nature 2025, 646: e33-e33. PMID: 41023408, DOI: 10.1038/s41586-025-09671-y.Commentaries, Editorials and LettersAltmetricPsilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
Shao L, Liao C, Davoudian P, Savalia N, Jiang Q, Wojtasiewicz C, Tan D, Nothnagel J, Liu R, Woodburn S, Bilash O, Kim H, Che A, Kwan A. Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors. Nature 2025, 642: 411-420. PMID: 40175553, PMCID: PMC12188471, DOI: 10.1038/s41586-025-08813-6.Peer-Reviewed Original ResearchCitationsAltmetricClassification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression
Aboharb F, Davoudian P, Shao L, Liao C, Rzepka G, Wojtasiewicz C, Indajang J, Dibbs M, Rondeau J, Sherwood A, Kaye A, Kwan A. Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression. Nature Communications 2025, 16: 1590. PMID: 39939591, PMCID: PMC11822132, DOI: 10.1038/s41467-025-56850-6.Peer-Reviewed Original ResearchCitationsAltmetricKetamine vs Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: Do We Need More Data?
Rhee T, Shim S, Davoudian P, Espinoza R, McIntyre R. Ketamine vs Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: Do We Need More Data? The Journal Of Clinical Psychiatry 2025, 86 PMID: 39898891, DOI: 10.4088/jcp.24br15655.Peer-Reviewed Original ResearchCitations
2024
Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI
Tiwari P, Davoudian P, Kapri D, Vuruputuri R, Karaba L, Sharma M, Zanni G, Balakrishnan A, Chaudhari P, Pradhan A, Suryavanshi S, Bath K, Ansorge M, Fernandez-Ruiz A, Kwan A, Vaidya V. Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron 2024, 112: 3697-3714.e6. PMID: 39321791, PMCID: PMC11581910, DOI: 10.1016/j.neuron.2024.08.016.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricHyperconnectivity of Two Separate Long-Range Cholinergic Systems Contributes to the Reorganization of the Brain Functional Connectivity during Nicotine Withdrawal in Male Mice
Carrette L, Kimbrough A, Davoudian P, Kwan A, Collazo A, George O. Hyperconnectivity of Two Separate Long-Range Cholinergic Systems Contributes to the Reorganization of the Brain Functional Connectivity during Nicotine Withdrawal in Male Mice. ENeuro 2023, 10: eneuro.0019-23.2023. PMID: 37295945, PMCID: PMC10306126, DOI: 10.1523/eneuro.0019-23.2023.Peer-Reviewed Original ResearchCitationsAltmetric5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson S, Gregg I, Dibbs M, Liao C, Wu H, Davoudian P, Woodburn S, Wehrle P, Sprouse J, Sherwood A, Kaye A, Pittenger C, Kwan A. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology 2023, 48: 1257-1266. PMID: 37015972, PMCID: PMC10354037, DOI: 10.1038/s41386-023-01572-w.Peer-Reviewed Original ResearchCitationsAltmetricShared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin
Davoudian P, Shao L, Kwan A. Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chemical Neuroscience 2023, 14: 468-480. PMID: 36630309, PMCID: PMC9898239, DOI: 10.1021/acschemneuro.2c00637.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link